News for 'Sun Pharma'

Budget 2026 is cautious and also focussed on the long-term journey

Budget 2026 is cautious and also focussed on the long-term journey

Rediff.com10 Feb 2026

This year's Economic Survey and the Union Budget were more closely followed for more reasons than one.

What India gives, and what it gets: Highlights of India-US interim trade deal

What India gives, and what it gets: Highlights of India-US interim trade deal

Rediff.com7 Feb 2026

Both countries commit to provide each other preferential market access in sectors of respective interest on a sustained basis

Patients to benefit from GST cut, but pharma firms may face margin pressure

Patients to benefit from GST cut, but pharma firms may face margin pressure

Rediff.com12 Sep 2025

The rationalisation of goods and services tax (GST), announced on Wednesday, directly lowers the cost of everyday medical consumables, and also high-end therapies in oncology and rare diseases, helping reduce out-of-pocket patient expenditure and better adherence to medication.

Sensex jumps 487 points on optimism over India-EU FTA

Sensex jumps 487 points on optimism over India-EU FTA

Rediff.com28 Jan 2026

From the 30-Sensex firms, Bharat Electronics surged nearly 9 per cent post its December quarter earnings. Eternal, Bajaj Finance, Power Grid, Trent, Mahindra & Mahindra and UltraTech Cement were the other major gainers. Maruti, Sun Pharma, Infosys and Bharti Airtel were among the other laggards.

Sensex drops 245 points on persistent foreign fund outflows

Sensex drops 245 points on persistent foreign fund outflows

Rediff.com14 Jan 2026

From the 30-Sensex firms, Tata Consultancy Services, Asian Paints, Maruti, Sun Pharma, Hindustan Unilever, ICICI Bank, Kotak Mahindra Bank, Tech Mahindra, HDFC Bank and Larsen & Toubro were among the biggest laggards. On the other hand, Tata Steel, NTPC, Axis Bank and UltraTech Cement were among the gainers.

Investors lost Rs 9.40 lakh cr in Budget Sunday crash

Investors lost Rs 9.40 lakh cr in Budget Sunday crash

Rediff.com1 Feb 2026

The market capitalisation of BSE-listed companies eroded by Rs 9,40,581.75 crore to Rs 4,50,61,658.60 crore (USD 4.90 trillion) in a single day.

Sensex tanks over 1,000 points, Nifty tumble over 1%

Sensex tanks over 1,000 points, Nifty tumble over 1%

Rediff.com20 Jan 2026

From the 30-Sensex firms, Eternal declined by 4.02 per cent, followed by Bajaj Finance (3.88 per cent), Sun Pharma, InterGlobe Aviation, Trent, Asian Paints, Mahindra & Mahindra and Bajaj Finserv. HDFC Bank emerged as the only gainer from the pack.

Can MFN Pricing Reshape India-US Pharma Equation?

Can MFN Pricing Reshape India-US Pharma Equation?

Rediff.com5 Jun 2025

US accounts for a large part of revenue for top Indian pharma companies like Gland Pharma (54 percent), Dr Reddy's (53 per cent), and Aurobindo Pharma (48 per cent).

Centre mandates blue strip on antimicrobial drugs to curb overuse

Centre mandates blue strip on antimicrobial drugs to curb overuse

Rediff.com24 Jan 2026

The Union health ministry has issued draft rules to mandate a blue vertical strip on all antimicrobial drug labels, aiming to rein in over-the-counter misuse and tackle India's growing antimicrobial resistance (AMR) problem.

Smallcap To Watch Out For In 2026

Smallcap To Watch Out For In 2026

Rediff.com4 Feb 2026

After two years of strong gains, smallcap stocks fell sharply in 2025, but the correction may be setting up opportunities for long-term investors.

Stock markets end higher on rally in Infosys shares

Stock markets end higher on rally in Infosys shares

Rediff.com16 Jan 2026

Tech Mahindra, HCL Tech, State Bank of India, UltraTech Cement and HDFC Bank were also among the gainers. In contrast, Eternal, Asian Paints, Bharat Electronics, Sun Pharma and Maruti were among the laggards.

Coldrif syrup maker used industrial-grade materials: ED

Coldrif syrup maker used industrial-grade materials: ED

Rediff.com3 Dec 2025

An Enforcement Directorate (ED) probe has revealed that the manufacturer of Coldrif syrup, linked to the deaths of at least 20 children in Madhya Pradesh, used industrial-grade raw materials without quality checks. The investigation also found that Tamil Nadu Drugs Control Department officials were in frequent contact with the company but failed to conduct mandated inspections.

Sensex slips 43 pts; IT shares fall on profit-taking

Sensex slips 43 pts; IT shares fall on profit-taking

Rediff.com23 Dec 2025

Among Sensex firms, Infosys, Bharti Airtel, Adani Ports, Sun Pharma, Tech Mahindra, Eternal, Axis Bank and Maruti were the major laggards. However, ITC, UltraTech Cement, Tata Steel and HDFC Bank were among the gainers.

Pharma Inc hopes for fair deal as Donald Trump announces 25% tariffs

Pharma Inc hopes for fair deal as Donald Trump announces 25% tariffs

Rediff.com31 Jul 2025

India's pharmaceuticals and medical devices industries are still hopeful that trade negotiations with the US could cut a fairer deal for both sides, after President Donald Trump announced a 25 per cent tariff rate on India on a social networking platform without divulging the finer details.

Ambitious, futuristic: PM Modi lauds Sitharaman's 9th Budget

Ambitious, futuristic: PM Modi lauds Sitharaman's 9th Budget

Rediff.com1 Feb 2026

Reiterating Sitharaman's statement that this is a youth power budget, Modi emphasised that the provisions made in the budget will prepare leaders, innovators and creators across different sectors.

Budget 2026: Time To Fix The Weak Link In R&D Ecosystem

Budget 2026: Time To Fix The Weak Link In R&D Ecosystem

Rediff.com31 Jan 2026

Restoring weighted tax deductions and adopting a petty patents regime can foster firm-level innovative activity critical for competitiveness, points out Nagesh Kumar.

'Money Comes Only When Markets Do Well'

'Money Comes Only When Markets Do Well'

Rediff.com4 Feb 2026

'Given that India underperformed emerging markets by 28 per cent in 2025, the worst performance in over 30 years, the timing of the sharp STT hike could have been better.'

Sensex, Nifty tank nearly 1%

Sensex, Nifty tank nearly 1%

Rediff.com9 Jan 2026

From the 30-Sensex firms, NTPC, ICICI Bank, Adani Ports, Bharti Airtel, Sun Pharma and Bajaj Finance were among the biggest laggards. However, Asian Paints, HCL Tech, Bharat Electronics and Reliance Industries were among the gainers.

Dr Reddy's profit down 14% on low Lenalidomide US sales

Dr Reddy's profit down 14% on low Lenalidomide US sales

Rediff.com22 Jan 2026

Pharma major Dr Reddy's Laboratories (DRL) reported a 14 per cent year-on-year (Y-o-Y) drop in consolidated net profit to Rs 1,210 crore in the December quarter of FY 2025-26 (Q3FY26) on low sales of cancer drug Lenalidomide in the North American market. The firm's revenue from operations grew to Rs 8,727 crore in Q3FY26, a 4.4 per cent Y-o-Y increase from Rs 8,357 crore recorded for the same quarter last year.

Sensex sheds 367 points on foreign fund outflows

Sensex sheds 367 points on foreign fund outflows

Rediff.com26 Dec 2025

From the 30-Sensex firms, Bajaj Finance, Asian Paints, HCL Tech, Tata Consultancy Services, Eternal and Sun Pharma were among the biggest laggards. However, Titan, NTPC, Axis Bank, UltraTech Cement, Reliance Industries and Hindustan Unilever were the gainers.

Stock markets surge nearly 1% on last trading session of 2025

Stock markets surge nearly 1% on last trading session of 2025

Rediff.com31 Dec 2025

From the 30-Sensex firms, Tata Steel, Kotak Mahindra Bank, Reliance Industries, Axis Bank, Titan and Trent were among the biggest gainers. However, Tata Consultancy Services, Tech Mahindra, Infosys, Bajaj Finance and Sun Pharma, were the laggards.

Sigachi Industries CEO held over Telangana plant blast

Sigachi Industries CEO held over Telangana plant blast

Rediff.com28 Dec 2025

A top executive of Sigachi Industries has been arrested in connection with the explosion at its pharma plant in Telangana in June, which resulted in 54 deaths.

India, EU free trade deal to likely conclude on Jan 27

India, EU free trade deal to likely conclude on Jan 27

Rediff.com25 Jan 2026

India and the European Union are set to announce on January 27 the conclusion of negotiations and finalisation of a free trade agreement, which is aimed at boosting economic ties between the two regions amid disruptions in global trade due to US tariffs, an official said.

'Good night, Happy New Year': Maduro's 1st words after US capture

'Good night, Happy New Year': Maduro's 1st words after US capture

Rediff.com4 Jan 2026

The Venezuelan President and his wife Cilia Flores were earlier captured from Caracas after US President Donald Trump unilaterally sanctioned a military operation on Venezuelan soil.

Maduro, wife to appear in New York court today

Maduro, wife to appear in New York court today

Rediff.com5 Jan 2026

Venezuelan President Nicolas Maduro and his wife, Cilia Flores, are set to appear before a federal judge on Monday, after United States authorities confirmed that the case will be heard in the Southern District of New York on Sunday, CBS News reported.

Sensex down 376 points on selling in RIL, HDFC Bank

Sensex down 376 points on selling in RIL, HDFC Bank

Rediff.com6 Jan 2026

Reliance Industries cracked 4.42 per cent, while ITC, Kotak Mahindra Bank, InterGlobe Aviation, and HDFC Bank were also among the laggards. However, ICICI Bank, Sun Pharma, Hindustan Unilever, and State Bank of India were among the gainers.

Indian pharma firms not copying products of Swiss cos: Goyal

Indian pharma firms not copying products of Swiss cos: Goyal

Rediff.com10 Jun 2025

Dismissing allegations that Indian phacosrmaceutical companies copy products of Swiss firms, Commerce and Industry Minister Piyush Goyal on Tuesday said it is a long-standing myth and India respects intellectual property rights and never steals technology from others. He said that Swiss pharmaceutical companies have not shown even a single instance that Indian companies have illegally copied any of their trademarks or patents or copyrighted technology.

Now, Isn't Shruti Sweet?

Now, Isn't Shruti Sweet?

Rediff.com22 Dec 2025

Shruti Ramachandran's style lives in that sweet spot where simplicity meets a quiet edge.

Paid Rs 1.35L Insurance Premium: 'Can I Get It Back?'

Paid Rs 1.35L Insurance Premium: 'Can I Get It Back?'

Rediff.com8 Jan 2026

Ask rediffGURU Naveenn Kummar your insurance mutual fund and personal finance-related questions.

Weak guidance may hit Sun Pharma in FY26

Weak guidance may hit Sun Pharma in FY26

Rediff.com1 Jun 2025

Despite a healthy performance in the fourth quarter of 2024-25 (Q4FY25), the stock of India's largest listed pharma company, Sun Pharmaceutical Industries (Sun Pharma), was under pressure on Friday due to a muted guidance. The company has guided for a high single-digit revenue growth for FY26, which is below what the Street was working with.

Sensex down 78 points on weak global trends

Sensex down 78 points on weak global trends

Rediff.com18 Dec 2025

Among Sensex firms, Sun Pharma, Tata Steel, Power Grid, Asian Paints, NTPC and Bharti Airtel were the biggest laggards. Tata Consultancy Services, Tech Mahindra, Infosys, Adani Ports, Axis Bank and HCL Tech were among the gainers.

Sensex jumps 448 points on fresh fund inflows

Sensex jumps 448 points on fresh fund inflows

Rediff.com19 Dec 2025

From the 30-Sensex firms, Bharat Electronics, Power Grid, Tata Motors Passenger Vehicles, Asian Paints, Reliance Industries, and Bajaj Finserv were among the biggest gainers. However, HCL Tech, Kotak Mahindra Bank, ICICI Bank, and Sun Pharma were the laggards.

Cough syrup deaths: Pharma co to face criminal action

Cough syrup deaths: Pharma co to face criminal action

Rediff.com8 Oct 2025

Tamil Nadu Government will take criminal action against a drug manufacturer, whose cough syrup has been banned in the wake of children's deaths in Madhya Pradesh, state minister Ma Subramanian said here on Wednesday.

'14+ Anti-Obesity Drugs In The Pipeline'

'14+ Anti-Obesity Drugs In The Pipeline'

Rediff.com13 Dec 2025

The semaglutide patent expiry next year could unleash a wave of generic versions from Indian drugmakers, with prices expected to go lower -- at least 80 per cent.

Stock markets end lower in volatile trade

Stock markets end lower in volatile trade

Rediff.com24 Dec 2025

From the 30-Sensex firms, InterGlobe Aviation, Sun Pharma, Asian Paints, Reliance Industries, Hindustan Unilever, and Tata Steel were among the biggest laggards. However, Trent, UltraTech Cement, Maruti, and Power Grid were among the gainers.

Sensex climbs 304 pts on buying in metal, auto and pharma shares

Sensex climbs 304 pts on buying in metal, auto and pharma shares

Rediff.com13 Aug 2025

Among Sensex firms, Bharat Electronics, Eternal, Mahindra & Mahindra, Kotak Mahindra Bank, Tata Motors and Power Grid were the gainers. However, Adani Ports, ITC, UltraTech Cement and Titan were among the laggards.

Weightloss Drugs Hit 1,000 Crore Mark

Weightloss Drugs Hit 1,000 Crore Mark

Rediff.com22 Dec 2025

'As more patients are prescribed these drugs, intolerance due to gastrointestinal and other side effects will become more visible, leading to higher discontinuation rates.'

Sensex rises 317 pts on gains in auto, pharma shares

Sensex rises 317 pts on gains in auto, pharma shares

Rediff.com15 Jul 2025

Stock markets snapped the four-day falling streak on Tuesday with the benchmark Sensex rebounding by 317 points on buying in auto and pharma shares amid a decline in retail inflation to a more than six-year low, nearing the RBI's comfort zone. The 30-share BSE Sensex climbed 317.45 points or 0.39 per cent to settle at 82,570.91. During the day, it jumped 490.16 points or 0.59 per cent to 82,743.62. The 50-share NSE Nifty edged higher by 113.50 points or 0.45 per cent to 25,195.80.

Indian pharma eyes US gains as $63.7 bn patent cliff nears

Indian pharma eyes US gains as $63.7 bn patent cliff nears

Rediff.com30 Jun 2025

The Indian pharmaceutical industry is likely to benefit from a major wave of patent expiries in the US, as small-molecule drugs worth $63.7 billion are expected to go off-patent between 2025-29, a 65 per cent rise over the previous five years, according to a report by Antique stock broking limited.

Trump slaps 100% tariffs on imported pharma products

Trump slaps 100% tariffs on imported pharma products

Rediff.com26 Sep 2025

United States President Donald Trump on Friday announced that his administration will impose a 100 per cent tariff on branded and patented pharmaceutical products beginning October 1, 2025, unless the manufacturing companies are building production facilities in the US.